TrialBlood2022

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.

Alexander Röth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.